Two gold-standard trials published in The New England Journal of Medicine on Wednesday help settle questions about two controversial therapies touted by many early in the pandemic with decidedly mixed results - failure for the antiparasite drug ivermectin and success for antibody-rich blood plasma from COVID-19 survivors. Ivermectin fails, convalescent plasma succeeds Neither study included patients infected or reinfected with the Omicron variant. "One-dose hybrid immunity was associated with an additional 94% lower risk of COVID-19 hospitalization, and two-dose hybrid immunity with an additional 90% lower risk of COVID-19 hospitalization," compared to natural immunity alone, the researchers said. The second study, using data from more than 5 million people in Sweden, found that "hybrid immunity" from a combination of previous infection and receipt of either one or two doses of a vaccine provided additional protection for at least nine months. Effectiveness against hospitalization or death ranged from 81.3% for CoronaVac to 89.7% for Pfizer/BioNTech's vaccine. Effectiveness against infection starting 14 days after vaccination completion ranged from 39.4% for Sinovac's CoronaVac to 64.8% for the Pfizer/BioNTech shots. One study of 22,566 people in Brazil who had recovered from COVID found that all four vaccines in use there - from Sinovac Biotech (SVA.O), AstraZeneca (AZN.L), Johnson & Johnson (JNJ.N), and Pfizer (PFE.N)/BioNTech (22UAy.DE) - provided significant additional protection. Vaccination after COVID-19 improves immunityĪlthough people who recover from COVID-19 usually gain some immune defenses against reinfection, they get additional protection from vaccines, especially against severe disease, according to two studies published on Thursday in The Lancet Infectious Diseases. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. This warning hasn't stopped the drug's popularity with some people seeking to treat COVID.April 1 (Reuters) - The following is a summary of some recent studies on COVID-19. The Food and Drug Administration has strongly urged against using the animal version of ivermectin to fight COVID-19, warning it can cause nausea, vomiting, abdominal pain, neurologic disorders and potentially severe hepatitis requiring hospitalization. There have already been some clinical trials done earlier in the pandemic that showed ivermectin is not effective against COVID-19. In their conclusion, the authors said, "Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19." In the large study, researchers in Brazil studied more than 1,300 patients, half of which received ivermectin and the other half a placebo. The study serves as more evidence for what health professionals have been saying for much of the pandemic: the cow and horse de-wormer shouldn't be used to treat COVID. The anti-parasitic ivermectin doesn't reduce the risk of hospitalization from COVID-19, according to a study published in the New England Journal of Medicine. A health worker shows a box containing a bottle of Ivermectin in Cali, Colombia, on July 21, 2020.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |